期刊文献+

乳腺癌患者组织及血清中EGFL7、P185蛋白的检测及临床意义 被引量:3

Detection and clinical significance of EGFL7 and P185 protein in tissues and serum of patients with breast cancer
原文传递
导出
摘要 目的检测表皮生长因子样结构域-7(EGFL7)及P185蛋白在乳腺癌患者癌组织及血清中的水平,分析其在组织中的表达水平与患者临床病理特征的关系。方法收集2016年3月至2018年3月在湖南省肿瘤医院就诊的60例乳腺癌患者为研究对象(观察组),同时选取同期来湖南省肿瘤医院就诊的乳腺良性病变患者60例为对照组。利用免疫组织化学二步法检测两组患者组织中EGFL7及P185蛋白的表达,利用酶联免疫吸附法(ELISA)检测两组患者血清中EGFL7及P185蛋白的水平。分析EGFL7及P185蛋白表达与乳腺癌患者临床病理特征的关系。结果观察组和对照组患者组织中EGFL7阳性表达率分别为65.00%(39/60)、28.33%(17/60),差异具有统计学意义(χ^2=16.205,P<0.001);两组患者P185阳性表达率分别为43.33%(26/60)、15.00%(9/60),差异具有统计学意义(χ^2=11.657,P=0.001)。观察组和对照组患者血清中EGFL7蛋白水平分别为(3.39±0.38)μg/ml、(2.75±0.31)μg/ml,差异具有统计学意义(t=10.109,P<0.001);两组患者血清中P185蛋白水平分别为(7.12±0.75)μg/ml、(6.08±0.62)μg/ml,差异具有统计学意义(t=8.279,P<0.001)。EGFL7阳性表达与肿瘤大小(χ^2=6.128,P=0.013)、TNM分期(χ^2=7.781,P=0.005)、淋巴结有无转移(χ^2=5.444,P=0.020)密切相关;P185阳性表达与肿瘤大小(χ^2=8.910,P=0.003)、TNM分期(χ^2=8.024,P=0.005)密切相关。结论EGFL7及P185蛋白在乳腺癌组织及血清中的水平较高,且其阳性表达均与肿瘤大小及TNM分期有关。EGFL7及P185蛋白在乳腺癌疾病进程中有重要作用。 Objective To detect the expressions of epidermal growth factor-like domain 7(EGFL7)and P185 protein in breast cancer tissues and serum,and to analyze the correlation between the expression levels of EGFL7 and P185 in tissues and clinicopathological parameters of breast cancer patients.Methods Sixty patients with breast cancer in Hunan Cancer Hospital from March 2016 to March 2018 were collected as observation group,and 60 patients with breast benign lesions in the hospital during the same period were selec-ted as control group.The expressions of EGFL7 and P185 protein in tissues of patients in the two groups were detected by immunohistochemical two-step method,and the levels of EGFL7 and P185 protein in serum of patients in the two groups were detected by enzyme-linked immunosorbent assay(ELISA).The relationships between the expressions of EGFL7 and P185 protein and clinicopathological parameters of breast cancer patients were analyzed.Results The positive rates of EGFL7 in tissues in the observation group and the control group were 65.00%(39/60)and 28.33%(17/60),and there was a significant difference between the two groups(χ^2=16.205,P<0.001).The positive rates of P185 in tissues in the two groups were 43.33%(26/60)and 15.00%(9/60),and there was a significant difference between the two groups(χ^2=11.657,P=0.001).The serum levels of EGFL7 protein in the observation group and the control group were(3.39±0.38)μg/ml and(2.75±0.31)μg/ml respectively,with a significant difference(t=10.109,P<0.001).The serum levels of P185 protein in the two groups were(7.12±0.75)μg/ml and(6.08±0.62)μg/ml respectively,with a significant difference(t=8.279,P<0.001).The positive expression of EGFL7 protein was closely related to tumor size(χ^2=6.128,P=0.013),TNM stage(χ^2=7.781,P=0.005)and metastasis(χ^2=5.444,P=0.020).The positive expression of P185 protein was closely related to tumor size(χ^2=8.910,P=0.003)and TNM stage(χ^2=8.024,P=0.005).Conclusion The levels of EGFL7 and P185 protein are high in breast cancer tissues and serum,and their positive expressions are related to tumor size and TNM stage.EGFL7 and P185 proteins play important roles in the progression of breast cancer.
作者 胡小波 夏明智 何悦 刘志华 Hu Xiaobo;Xia Mingzhi;He Yue;Liu Zhihua(First Department of Breast Surgery,Hunan Cancer Hospital,Changsha 410000,China)
出处 《国际肿瘤学杂志》 CAS 2019年第10期581-584,共4页 Journal of International Oncology
关键词 乳腺肿瘤 表皮生长因子样结构域-7 P185 Breast neoplasms Epidermal growth factor-like domain 7 P185
  • 相关文献

参考文献8

二级参考文献60

  • 1姚婵,来茂德.上皮间质转化(EMT)及其分子机制[J].国际遗传学杂志,2006,29(4):290-294. 被引量:25
  • 2Papila C,Uzun H,Balci H,et al. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.Med Oncol,2009,26:151-156 .
  • 3Bramwell VH,Doig GS,Tuck AB,et al.Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast cancer Res Treat,2009,114:503-511.
  • 4Leyland-Jones B,Smith BR.Serum HER2 testing in patients with HER2-positive breast cancer:the death knell tolls.Lancet Oncol,2011,12:286-295.
  • 5Brodowicz T,Wiltschke C,Budinsky A,et al.Soluble HER-2/Neu neutralizes biologic effects of anti-HER-2/Neu antibody on breast cancer cells in vitro.Int J Cancer,1997,73:875-879.
  • 6Ludovini V,Gori S,Colozza M,et al.Evaluation of serum HER2extracellular domain in early breast cancer patients:correlation with clinipathological parameters and survival.Ann Oncol,2008,19:883-890.
  • 7Goksel G, Taneli F, Uslu R, et al.Serum her-2/neu and surviving levels and heir relationship to histological parameters in early-stage brease cancer.J Int Med Res,2007,35:165-172.
  • 8Leary AF,Hanna WH,van de Vijver M J,et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.J Clin Oncol,2009,27:1694-1705.
  • 9Cameron D,Casey M,Press M,et al.A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses. Breast Cancer Res Treat,2008,112:533-543.
  • 10Fehem T,Gebauer G,Jager W.Clinical utility of serial serum CerbB-2 determinations in the follow-up breast cancer patients.Breast Cancer Res Treat,2002,25:97-106.

共引文献268

同被引文献25

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部